Summary & Overview
CPT 81438: Genomic Sequencing for Hereditary Neuroendocrine Tumor Disorders
CPT code 81438 represents genomic sequencing for hereditary neuroendocrine tumor disorders, specifically targeting duplication and deletion analysis. This procedure is essential for identifying genetic mutations that may predispose individuals to neuroendocrine tumors, enabling more precise diagnosis and informing treatment strategies. The code is most commonly utilized in independent laboratory settings, reflecting the specialized nature of genetic testing.
Key payers covered in this analysis include Blue Cross Blue Shield, Cigna Health, and UnitedHealthcare, all of which play significant roles in national reimbursement and coverage policies for genetic testing services. Readers will gain insights into clinical benchmarks, policy updates, and the broader context of hereditary cancer panel testing. The publication also addresses relevant modifiers, associated taxonomies, and ICD-10 diagnoses linked to neuroendocrine tumor disorders, providing a comprehensive overview of coding and billing considerations.
This summary offers a clear understanding of the clinical and administrative aspects of CPT code 81438, equipping stakeholders with the information needed to navigate evolving payer policies and regulatory requirements in the field of medical genetics.
CPT Code Overview
CPT code 81438 is used to report genomic sequencing procedures for hereditary neuroendocrine tumor disorders, specifically focusing on duplication and deletion analysis. This code is part of the broader category of hereditary cancer panels, which play a critical role in identifying genetic mutations associated with neuroendocrine tumors. The typical site of service for this procedure is an independent laboratory (POS 81), where specialized genetic testing is performed to support clinical decision-making and patient management.
Clinical & Coding Specifications
Clinical Context
A patient presents with a personal or family history suggestive of hereditary neuroendocrine tumor disorders, such as malignant carcinoid tumors affecting the gastrointestinal tract. The ordering provider, typically a specialist in medical genetics, requests genomic sequencing to assess for duplication or deletion mutations associated with these disorders. The procedure corresponding to CPT code 81438 is performed in an independent laboratory (Place of Service 81). The workflow involves specimen collection, laboratory analysis for relevant genetic alterations, and interpretation by a qualified genetics professional. Results inform diagnosis, prognosis, and potential management strategies for hereditary neuroendocrine tumor syndromes.
Coding Specifications
-
Modifier
26: Used to indicate the professional component of the service, such as interpretation of the genetic test results by a qualified provider. -
Modifier
59: Used to denote a distinct procedural service, typically when multiple procedures are performed and need to be reported separately.
| Modifier Code | Description |
|---|---|